TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01522391
Drug: Placebo for DPK-060 ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for DPK-060 ointment applied to the skin, two applications per day using approximately 3 mg ointment per cm2
Study: NCT02840552
Drug: 18F-Fluoromethylcholine (18F-FCH)
Normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCH PET/CT
Study: NCT00554229
Drug: ZD4054
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZD4054 10 mg oral tablet once daily
Study: NCT00554229
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo oral tablet once daily
Study: NCT00214942
Drug: ORAVESCENT Fentanyl Citrate
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03712878
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02389868
Drug: Lovastatin
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01353313
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone sodium succinate for intravenous administration (unpreserved, Solu-Cortef plain, Pfizer®, reconstituted with unpreserved normal saline to avoid exposure to the benzyl alcohol contained in preserved diluents), to be administered either intravenously or orally if no intravenous line is available at the same dose, and tapered as follows:~4mg/kg/day ¸ q 6 hours x 2 days, then 2mg/kg/day ¸ q 6 hours x 3 days; then~1mg/kg/day ¸ q 12 hours x 3 days; then 0.5mg/kg/d as a single dose x 2 days
Study: NCT01353313
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo to be administered either intravenously or orally if no intravenous line is available, at the same dose, and tapered as follows:~4mg/kg/day ¸ q 6 hours x 2 days, then 2mg/kg/day ¸ q 6 hours x 3 days; then~1mg/kg/day ¸ q 12 hours x 3 days; then 0.5mg/kg/d as a single dose x 2 days
Study: NCT02490111
Drug: DWJ1319
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02490111
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05164003
Drug: CORETOX®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to a total of 360U of the IP was allowed to be injected at three flexors; wrist, elbow and finger.
Study: NCT05164003
Drug: BOTOX®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to a total of 360U of the comparator was allowed to be injected at three flexors; wrist, elbow and finger.
Study: NCT00795717
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules given twice daily
Study: NCT01742013
Drug: GCJBP Laennec Inj.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug
Study: NCT01742013
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator
Study: NCT00954356
Drug: XPF-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral administration of 500 mg XPF-001 capsules (5 x 100 mg capsules)
Study: NCT00954356
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral administration of 5 x 100 mg Placebo capsules.
Study: NCT04571944
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suvorexant-matching placebo administered QD via oral tablet
Study: NCT00270881
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cyclophosphamide 120mg/kg
Study: NCT00939549
Drug: Cyclophosphamide/Glatiramer acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 50 mg/kg IV each day for four consecutive days. Glatiramer acetate 20 mg SC daily for 1 year.
Study: NCT04665453
Drug: Melatonin 0,1mg/kg oral syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonine in the form of syrup will be given orally to child.
Study: NCT02545504
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously on Days 1 and 15 of each treatment cycle
Study: NCT02545504
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle
Study: NCT02209155
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05207774
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 weeks intranasal placebo 0.6 ml per day. . 0.1 ml per puff
Study: NCT00812994
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04663763
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Usage: 1000mg/m2 d1-14 q3w
Study: NCT04609943
Drug: BAY1211163
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive one of the drug doses of BAY1211163 solution three times per day (TID) by inhalation for seven days.
Study: NCT04278599
Drug: Oral Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the test group, the patients will be administered Zinc Acetate tablets (equivalent to 30 mg of elemental zinc/day) for 6 weeks from the baseline. They will also be will be administered, topical corticosteroid paste- Triamcinolone acetonide- 0.1%, to be applied thrice a day till the lesions disappeared and the dosage will be tapered accordingly.The patients will be instructed to take the tablets and apply the paste after meals.The patients will be kept on a monthly follow-up for 3 months.
Study: NCT04278599
Drug: Oral placebo supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the control group, the patients will be administered Placebo tablets for 6 weeks from the baseline. They will also be administered, topical corticosteroid paste- Triamcinolone acetonide- 0.1%, to be applied thrice a day till the lesions disappeared and the dosage will be tapered accordingly.The patients will be instructed to take the tablets and apply the paste after meals.The patients will be kept on a monthly follow-up for 3 months.
Study: NCT00689039
Drug: AZD1305
Approvals — FDA: no, EMA: no, PMDA: no
Description: ER tablet, administered as single and repeated doses.
Study: NCT00689039
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, administered as single and repeated doses.
Study: NCT04426734
Drug: Topical Prednisolone Acetate 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroid (Pred Forte, prednisolone acetate 1%) standard of care tapered treatment regimen of~8x/day week 1 4x/day week 2 2x/day week 3~1x/day week 4~Visit schedule: Baseline, Day 3, Day 7, Day 14, and Day 30
Study: NCT00629980
Drug: AzaSite®
Approvals — FDA: no, EMA: no, PMDA: no
Description: ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for \~26 days
Study: NCT04076865
Drug: EMLA (lidocaine) +Itch (Histamine and cowhage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cutaneous anaesthesia: will be topically induced by using EMLA cream 5%, a local anaesthetic cream consisting of equal parts of lidocaine and prilocaine (1g contains 25 mg of lidocaine and 25 mg of prilocaine, AstraZeneca A/S, Albertslund, Denmark).~Histamine: To deliver histamine, standard allergy skin prick test (SPT) lancets are applied.~Cowhage: Cowhage spicules are 1-2 mm in length and have diameter of 1-3 um at their tip, once inserted into the epidermis, the spicules evoke a moderate sensation of itch and to a lesser extent sensations of burning and stinging pain.
Study: NCT01632527
Drug: HuCNS-SC cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: HuCNS-SC cells transplantation directly into the subretinal space of one eye (Study eye) in a single transplant procedure.
Study: NCT00619034
Drug: Latanoprost, diclofenac and dorzolamide (eyedrops)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 eyedrop twice daily in one week
Study: NCT00619034
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dicolfenac eyedrops twice daily i one eye
Study: NCT02997215
Drug: Saline Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline infusion at same rate as intervention group during surgery
Study: NCT02155660
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benralizumab subcutaneously on study week 0 until study week 48 inclusive
Study: NCT02257398
Drug: GSK2140944
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2140944 is available in dose strength 1000 mg and 1800 mg for single IV dose over 2 hours administration as a pale yellow to greyish yellow cake for reconstitution
Study: NCT02257398
Drug: GSK2140944 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2140944 placebo is 0.9% sodium chloride available for single IV dose over 2 hours administration.
Study: NCT04827069
Drug: Clifutinib Besylate
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: receive oral Clifutinib Besylate once daily until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days
Study: NCT00216346
Drug: Paromomycin sulfate
Normalized name: Paromomycin Sulfate
DrugBank: Paromomycin (DB01421)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04184050
Drug: MK-4002
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT04651153
Drug: UCB7853
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive UCB7853 at pre-specified time-points.
Study: NCT01189396
Drug: Placebo DPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo DPI with 0 mcg Albuterol/inhalation
Study: NCT03812224
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection once a month
Study: NCT01101321
Drug: Reformulated OXY (Totowa) (oxycodone HCl)
Normalized name: Oxy Gard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reformulated OXY 80-mg tablet (Totowa) x 1 dose taken without food.
Study: NCT01101321
Drug: Reformulated OXY (Wilson) (oxycodone HCl)
Normalized name: Oxy Gard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reformulated OXY 80-mg tablet (Wilson) x 1 dose taken without food.
Study: NCT02678182
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1250 mg/m2/day, 21 day cycle
Study: NCT02678182
Drug: MEDI4736 (Durvalumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV treatment on days 1\&15 of 28 day cycle
Study: NCT00104299
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 mg/kg/day orally for months 4-6
Study: NCT03215056
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03371498
Drug: Methylprednisolone placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventilated patients presenting moderate to severe ARDS with a procollagen III alveolar level above 9 µg/L
Study: NCT00575003
Drug: CYT003-QbG10
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 subcutaneous injections
Study: NCT00431132
Drug: estradiol, 10 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, administered intravaginally twice weekly
Study: NCT01447758
Drug: LEO 29102
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cream, 1,7mg/cm2 BSA, BID, 7 days In Cohort I, II and III, 6 weeks in Cohort IV
Study: NCT01447758
Drug: LEO 29102 Cream Vehicle
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cream, 1,7mg/cm2 BSA, BID, 7 days in Cohort I and II, 6 weeks in Cohort IV
Study: NCT03826641
Drug: HCP1805
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin/Metformin (Xigduo XR) 10/1000mg
Study: NCT01071902
Drug: Moxidex otic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
Study: NCT02085460
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02197884
Drug: JNJ-54861911, 25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-54861911, 25 mg tablet orally on Day 1 and Day 9.
Study: NCT02197884
Drug: Clarithromycin 500 mg
Normalized name: clarithromycin 500 MG
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin 500 mg immediate release tablet orally twice daily from Day 5 to Day 12.
Study: NCT01440231
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo administered by subcutaneous injection, once weekly
Study: NCT03976882
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01673204
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01619176
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: methotrexate: 7.5mg/week to 15mg/week for 3 months
Study: NCT01619176
Drug: non-steroidal anti-inflammatory drug (NSAID)
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID: 100mg twice a day for 3 months
Study: NCT03178149
Drug: ASP7317
Approvals — FDA: no, EMA: no, PMDA: no
Description: subretinal injection
Study: NCT04330326
Drug: Metabolic Cofactor Supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in active treatment will receive dietary supplementation with N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside, and serine, administered as a mixture. Half dosage of the co-factors will be given for two weeks (one dose taken just after dinner), and full dosage for 8 weeks (two equal doses taken just after breakfast and dinner).
Study: NCT04330326
Drug: Sorbitol
Normalized name: Sorbitol
DrugBank: Sorbitol (DB01638)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As placebo, sorbitol (5 g) flavored with strawberry aroma and coloring agent will be given. Sorbitol is widely used due to its solubility in water. It's approved by the U.S. Food and Drug Administration (FDA).
Study: NCT03907852
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: lymphodepletion chemotherapy
Study: NCT01048593
Drug: IBI-10090
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intraocular injection
Study: NCT03265964
Drug: Uridine
Normalized name: Uridine
DrugBank: Uridine (DB02745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uridine is the active treatment in this clinical trial.
Study: NCT03265964
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill placebo is the inactive treatment comparator in this clinical trial.
Study: NCT01258738
Drug: Background NSAID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will continue to take a concomitant background non steroidal anti inflammatory drug(NSAID)as prescribed by their attending physician. The name and dose of this NSAID is the decision of the attending physician.
Study: NCT01258738
Drug: Background NSAID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will continue to take a concomitant background non steroidal anti inflammatory drug(NSAID)as prescribed by attending physician (dose drug selection as tolerated and agreed upon by the attending Physician).
Study: NCT01211795
Drug: topical intraoral ketoprofen gel
Normalized name: ketoprofen Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% ketoprofen oral gel is applied once daily by cotton swab to a branch of the trigeminal nerve on the maxillary gingival mucosa above the 2nd and 3rd molars. The swab is held in place for 2 minutes at the same time once daily.
Study: NCT02418000
Drug: E6201
Normalized name: TRACH STOMA PROTECTOR,CLOTH WHITE BE6201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Group Assignment
Study: NCT00080158
Drug: fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00087152
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1,000 mg/m\^2 by mouth twice daily Days 1-14 of each 21 day cycle
Study: NCT00689611
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03172026
Drug: Placebo 300 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo will be started within two weeks of discharge from inpatient rehabilitation, which most often will occur from 4-6 weeks after stroke onset.
Study: NCT00508001
Drug: Best Supportive Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Best Supportive Care
Study: NCT04419558
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile solution for injection
Study: NCT02205580
Drug: continuous intravenous sufentanil 0.02μg•kg-1•h-1 infusion
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02205580
Drug: continuous intravenous sufentanil 0.03μg•kg-1•h-1 infusion
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02205580
Drug: continuous intravenous sufentanil 0.04μg•kg-1•h-1 infusion
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01486979
Drug: estradiol, 25 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: One vaginal tablet once daily in the morning during the first two weeks of treatment followed by one vaginal tablet twice weekly in the morning for 10 weeks
Study: NCT01787123
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day course of intravenous normal saline started within 4 days of ictus
Study: NCT01226134
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsules,thrice a day for four weeks
Study: NCT04298320
Drug: AIN 457
Normalized name: Ainsliaea fragrans top extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIN457 was administered 150mg or 300mg ih every 2 weeks
Study: NCT01735422
Drug: r-hLH
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovulation triggering will be performed using a single injection of r-hLH injection subcutaneously at a dose of 825 or 2750 or 5500 or 11,000 or 22,000 IU as soon as follicles satisfy the criteria for follicular development, that is at least 1 follicle with diameter \>= 18 mm, not more than 5 follicles with diameter \>= 15 mm and with E2 levels less than 9000 picomoles per liter (pmol/L).
Study: NCT01735422
Drug: u-hCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovulation triggering will be performed using a single injection of 5000 IU of u-hCG as soon as follicles satisfy the criteria for follicular development, that is at least 1 follicle with diameter \>= 18 mm, not more than 5 follicles with diameter \>= 15 mm and with E2 levels less than 9000 picomoles per liter (pmol/L).
Study: NCT00787527
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m\^2 by vein over 1 hour on Day 1 of 21 day cycle
Study: NCT00787527
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m\^2 by vein over 15 minutes on Day 1 of 21 day cycle
Study: NCT02485873
Drug: Vitamin K antagonists
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: As prescribed by treating physicians
Study: NCT04151212
Drug: BAT5906 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Signal dose escalation starting from 0.3mg. Route of administration: intravitreal injection
Study: NCT02973386
Drug: IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients in the experimental arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1 and day 22) during RT,followed by adjuvant chemotherapy with oral capecitabine(1000mg/m2/ twice a day for 14 days)every three weeks for eight cycles at 4 weeks later after RT.
Study: NCT04251130
Drug: 2-(2-([18F]fluoro)pyridin-4-yl)-9H-pyrrolo[2,3-b:4,5-c']dipyridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: A small molecule aimed for binding and PET-imaging of aggregated tau protein in the human brain.
Study: NCT01561014
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02807051
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily, 500-mg dose (one 500-mg tablet) administered every 8 to 12 hours on Day 8 through the morning of Day 12
Study: NCT02807051
Drug: Pacritinib and Clarithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: On Day 12, a single oral 400-mg dose of pacritinib was co-administered with the final 500-mg dose of clarithromycin
Study: NCT00000125
Drug: Topical ocular hypotensive eye drops.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ocular hypotensive eye drops.
Study: NCT04100083
Drug: Spironolactone 50 MG
Normalized name: spironolactone 50 MG
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study visit timeline: initial visit \[consent and enrollment followed by baseline exam (0 months), 3 months, 6 months, and follow up at 7 months, with optional treatment extension period for up to one year of total treatment during which patients will follow up every 3 months~The drug will be taken via oral tablets once daily for a duration of 6 months. Patients will be instructed to continue any current treatment regimen for hidradenitis suppurativa that was initiated at least 4 weeks prior to their enrollment in the study. Patients will be instructed to avoid potassium supplements and foods containing high levels of potassium, including salt substitutes, which could potentially lead to hyperkalemia. They will be instructed to avoid medications listed in the exclusion criteria.
Study: NCT02214381
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04100083
Drug: Spironolactone 100mg
Normalized name: SPIRONOLACTONE 100MG TAB
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study visit timeline: initial visit \[consent and enrollment followed by baseline exam (0 months), 3 months, 6 months, and follow up at 7 months, with optional treatment extension period for up to one year of total treatment during which patients will follow up every 3 months~The drug will be taken via oral tablets once daily for a duration of 6 months. Patients will be instructed to continue any current treatment regimen for hidradenitis suppurativa that was initiated at least 4 weeks prior to their enrollment in the study. Patients will be instructed to avoid potassium supplements and foods containing high levels of potassium, including salt substitutes, which could potentially lead to hyperkalemia. They will be instructed to avoid medications listed in the exclusion criteria.